Benidipine rescued impaired neurite outgrowth in PARK2-DA neurons following treatment at 10 μM for 6 days. In U251 cells, Benidipine alone stimulated ΔΨm dissipation (1.5-fold). In Vero cells, Benidipine hydrochloride produced a dose-dependent reduction in intracellular HTNV S segment RNA compared with the DMSO vehicle, with an IC50 of 3.063 μM. Benidipine also rescued impaired neurite outgrowth in PARK6-DA neurons following treatment at 10 μM for 6 days. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Benidipine rescues neurite outgrowth in PARK2-derived neurons
Cell-based study · PARK2-derived neurons; n = 4 independent biological replicates [1]
PARK2-derived neurons were treated with benidipine or DMSO. Benidipine rescued impaired neurite outgrowth in PARK2-DA neurons.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- for 6 days
- Method
- treated with DMSO or benidipine
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Benidipine
The paper names Benidipine without stating the salt or form; not verified as the hydrochloride form supplied as A11730. No dose conversion or lot validation.
Results > A Calcium Channel Antagonist Prevented Rotenone-Induced Apoptosis and Rescued Impaired Neurite Outgrowth in PARK2-Dopaminergic Neurons (S51); Figure 3 legend (S138, S140)
Neurite length: Neurite length; comparator: DMSO — Results > A Calcium Channel Antagonist Prevented Rotenone-Induced Apoptosis and Rescued Impaired Neurite Outgrowth in PARK2-Dopaminergic Neurons (S51); Figure 3 legend (S138)
In U251, benidipine alone stimulated ∆Ψm dissipation
Cell-based study · U251 [2]
U251 cells were treated with Benidipine at 1 µM. Benidipine alone stimulated ΔΨm dissipation (1.5-fold).
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 5–7 days
- Vehicle
- 0.1% DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Benidipine
The paper names Benidipine without stating the salt or form; not verified as the hydrochloride form supplied as A11730. No dose conversion or lot validation.
2. Materials and Methods > 2.6. Determination of Inner Mitochondrial Membrane Potential (ΔΨm) (S24); 3. Results (S92, S95); Figure 8 legend (S167)
normalized percentage of U251 cells with dissipated ΔΨm: normalized percentage of U251 cells with dissipated ΔΨm; comparator: vehicle/control — 3. Results (S95); Figure 8 legend (S167)
Benidipine reduces intracellular HTNV S segment RNA
Cell-based study · Vero cells [3]
Vero cells received Benidipine hydrochloride during and after virus adsorption. Compared with the DMSO vehicle, treatment produced a dose-dependent reduction in intracellular HTNV S segment RNA, with an IC50 of 3.063 μM.
Literature-Reported Treatment Conditions
- Exposure duration
- 1 hour prior to HTNV infection
- Method
- added during and after virus adsorption
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: HTNV MOI) of 1. Compound effect isolated by the comparison: in comparison with the DMSO vehicle.
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: Benidipine hydrochloride; Compound label in the paper: BENIDIPINE
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Benidipine hydrochloride inhibits Hantaan virus infection in different cell lines (S44, S45, S46)
relative intracellular RNA levels of the HTNV S segment: relative intracellular RNA levels of the HTNV S segment; comparator: DMSO vehicle — Results > Benidipine hydrochloride inhibits Hantaan virus infection in different cell lines (S45, S46)
Benidipine rescues neurite outgrowth in PARK6-DA neurons
Cell-based study · PARK6-DA neurons; n = 4 independent biological replicates [1]
PARK6-DA neurons were treated with benidipine or DMSO. Benidipine rescued impaired neurite outgrowth.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- for 6 days
- Method
- treated with DMSO or benidipine
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Benidipine
The paper names Benidipine without stating the salt or form; not verified as the hydrochloride form supplied as A11730. No dose conversion or lot validation.
Results > A Calcium Channel Antagonist Displayed Neuroprotective Effects against Dopaminergic Neurons Derived from a PARK6 Patient-Specific iPSC Line (S61); Figure 4 legend (S149, S150)
Neurite length: Neurite length; comparator: DMSO — Results > A Calcium Channel Antagonist Displayed Neuroprotective Effects against Dopaminergic Neurons Derived from a PARK6 Patient-Specific iPSC Line (S61); Figure 4 legend (S149)